BiomX (PHGE) Projected to Post Earnings on Tuesday

BiomX (NYSEAMERICAN:PHGE) is expected to be releasing its results before the market opens on Tuesday, March 24th. Analysts expect BiomX to post earnings of ($4.61) per share for the quarter.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. On average, analysts expect BiomX to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

BiomX Price Performance

Shares of PHGE opened at $5.48 on Tuesday. The firm has a market capitalization of $8.71 million, a price-to-earnings ratio of -0.22 and a beta of 1.68. BiomX has a 1-year low of $1.50 and a 1-year high of $14.71. The company has a 50-day moving average of $4.80 and a 200 day moving average of $6.40.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Alyeska Investment Group L.P. purchased a new position in BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX as of its most recent filing with the Securities and Exchange Commission (SEC). 40.57% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a research report on Monday, March 9th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, BiomX presently has a consensus rating of “Hold” and a consensus target price of $26.00.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.